Staging ::: VER CORREOS
España
Acceder
  1. Inicio
  2. Perfil de Euratom
  3. Participaciones

Participaciones del usuario Euratom - Buscando valor

Foro:
Bolsa (185) | Buscando valor (6)
Euratom 17/10/25 10:40
Ha respondido al tema Novo Nordisk (NOV)
Hace 3 días:Hace 2 días:Hace 1 día:Hace 0 días:Uno llega a preguntarse: ¿porqué llegan de repente TANTAS noticias juntas?El 4 de noviembre se presentan resultados del Q3 2025, donde se verá el impacto real de las medidas de eficiencia del nuevo CEO, de los aranceles reales impuestos por EE.UU., de la competencia con otras farmaceuticas, del sesgo hacia mayor investigación en dosis/edades/enfermedades de semaglutida...Saludos
Euratom 02/10/25 08:47
Ha respondido al tema Novo Nordisk (NOV)
 El negocio de Trump con las farmacéuticas convence al mercado: exención de aranceles a cambio de medicamentos más baratos en EEUU https://www.eleconomista.es/mercados-cotizaciones/noticias/13571579/10/25/el-negocio-de-trump-con-las-farmaceuticas-convence-al-mercado-exencion-de-aranceles-a-cambio-de-medicamentos-mas-baratos-en-eeuu.htmlSubidas de más del 8% en Alemania para Novo y de casi el 7% en NY. Otras como Pfizer o Moderna suben tambien un 7%, Roche casi un 9%.Saludos
Euratom 18/09/25 14:51
Ha respondido al tema Novo Nordisk (NOV)
https://www.nejm.org/doi/full/10.1056/NEJMoa2500969RESULTSA total of 205 participants were randomly assigned to receive oral semaglutide, and 102 to receive placebo. The estimated mean change in body weight from baseline to week 64 was -13.6% in the oral semaglutide group and -2.2% in the placebo group (estimated difference, -11.4 percentage points; 95% confidence interval, -13.9 to -9.0; P<0.001). Participants in the oral semaglutide group were significantly more likely than those in the placebo group to have body-weight reductions of 5% or more, 10% or more, 15% or more, and 20% or more (P<0.001 for all comparisons) and to have an improved IWQOL-Lite-CT Physical Function score (P<0.001). Gastrointestinal adverse events were more common with oral semaglutide than with placebo (74.0% vs. 42.2%).CONCLUSIONSOral semaglutide at a dose of 25 mg once daily resulted in a greater mean reduction in body weight than placebo in participants with overweight or obesity. (Funded by Novo Nordisk; OASIS 4 ClinicalTrials.gov number, NCT05564117.).La aprobación de la FDA del tratamiento oral contra la obesidad podría llegar a finales de 2025. Saludos
Euratom 10/09/25 13:29
Ha respondido al tema Novo Nordisk (NOV)
https://es.investing.com/news/stock-market-news/bernstein-mejora-la-calificacion-de-novo-nordisk-a-superar-por-mercado-de-farmacos-contra-la-obesidad-de-130000-millones-de-dolares-3298982?utm_medium=feed&utm_source=googlenews&utm_campaign=googlenews-es-stocks
Euratom 10/09/25 10:17
Ha respondido al tema Novo Nordisk (NOV)
https://www.investegate.co.uk/announcement/gnw/novo-nordisk-a-s-class-b--0qiu/novo-nordisk-to-streamline-operations-and-rei-/9097599 Novo Nordisk announced a company-wide transformation to streamline operations and focus on growth opportunities within diabetes and obesity, expecting to reduce approximately 9,000 roles globally. This restructuring is projected to yield annualised savings of DKK 8 billion by the end of 2026, which will be reinvested into growth initiatives. The company anticipates incurring DKK 8 billion in one-off restructuring costs, primarily in the third quarter of 2025, leading to a revised full-year 2025 operating profit growth outlook of 4-10% at CER, compared to the previous expectation of 10-16%. Depreciation, amortisation and impairment losses are now expected to be around DKK 21 billion. 
Euratom 06/08/25 11:55
Ha respondido al tema Novo Nordisk (NOV)
Sin comentarios